50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Cash Holders STILL Aren’t Taking Steps to Prepare (Ad)pixel
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Cash Holders STILL Aren’t Taking Steps to Prepare (Ad)pixel
'Crucial' vote could move Italy to right; many might boycott
China using civilian ships to enhance navy capability, reach
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Cash Holders STILL Aren’t Taking Steps to Prepare (Ad)pixel
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Cash Holders STILL Aren’t Taking Steps to Prepare (Ad)pixel
'Crucial' vote could move Italy to right; many might boycott
China using civilian ships to enhance navy capability, reach
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Cash Holders STILL Aren’t Taking Steps to Prepare (Ad)pixel
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Cash Holders STILL Aren’t Taking Steps to Prepare (Ad)pixel
'Crucial' vote could move Italy to right; many might boycott
China using civilian ships to enhance navy capability, reach
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
Cash Holders STILL Aren’t Taking Steps to Prepare (Ad)pixel
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
Cash Holders STILL Aren’t Taking Steps to Prepare (Ad)pixel
'Crucial' vote could move Italy to right; many might boycott
China using civilian ships to enhance navy capability, reach
NASDAQ:TWST

Twist Bioscience - TWST Stock Forecast, Price & News

$33.44
-0.20 (-0.59%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$32.13
$34.23
50-Day Range
$33.44
$56.56
52-Week Range
$25.07
$139.99
Volume
1.02 million shs
Average Volume
867,167 shs
Market Capitalization
$1.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.00

Twist Bioscience MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
61.5% Upside
$54.00 Price Target
Short Interest
Bearish
10.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.38mentions of Twist Bioscience in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$836,768 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.53) to ($4.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

840th out of 1,080 stocks

Biological Products, Except Diagnostic Industry

136th out of 172 stocks

TWST stock logo

About Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Stock News Headlines

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green Sells 8,514 Shares
10 Cathie Wood Stocks to Buy Before the Bull Run Starts
10 Healthcare Stocks Making Moves After Earnings
Twist Bioscience Q3 Results Top Estimates
Twist Bioscience Earnings Preview
TWST Crosses Above Average Analyst Target
SNIA Announces DNA Data Storage Technology Affiliate
See More Headlines
Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Company Calendar

Last Earnings
8/05/2022
Today
9/24/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/28/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TWST
Fax
N/A
Employees
652
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.00
High Stock Price Forecast
$56.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+61.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-152,100,000.00
Net Margins
-112.91%
Pretax Margin
-118.54%

Debt

Sales & Book Value

Annual Sales
$132.33 million
Book Value
$11.78 per share

Miscellaneous

Free Float
54,617,000
Market Cap
$1.88 billion
Optionable
Not Optionable
Beta
1.21

Key Executives

  • Dr. Emily Marine Leproust Ph.D. (Age 49)
    Co-Founder, Chairman, Pres & CEO
    Comp: $1.28M
  • Mr. James M. ThorburnMr. James M. Thorburn (Age 66)
    Chief Financial Officer
    Comp: $771.71k
  • Dr. William Charles Banyai Ph.D. (Age 67)
    Sr. VP of Advanced Devel., GM of Data Storage & Director
    Comp: $628.12k
  • Dr. Patrick John Finn Ph.D.Dr. Patrick John Finn Ph.D. (Age 50)
    Chief Commercial Officer
    Comp: $726.35k
  • Ms. Tracey Mullen M.B.A.
    Sr. VP of Operations
  • Mr. Kevin B. Yankton (Age 55)
    VP & Chief Accounting Officer
  • Mr. Siyuan Chen
    Chief Technology Officer
  • Dr. Aaron K. Sato Ph.D.
    Chief Scientific Officer
  • Mr. Dennis Cho (Age 51)
    Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer
  • Ms. Paula  GreenMs. Paula Green (Age 54)
    Sr. VP of HR













TWST Stock - Frequently Asked Questions

Should I buy or sell Twist Bioscience stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TWST shares.
View TWST analyst ratings
or view top-rated stocks.

What is Twist Bioscience's stock price forecast for 2022?

4 brokerages have issued 1 year price objectives for Twist Bioscience's shares. Their TWST share price forecasts range from $50.00 to $56.00. On average, they anticipate the company's stock price to reach $54.00 in the next year. This suggests a possible upside of 61.5% from the stock's current price.
View analysts price targets for TWST
or view top-rated stocks among Wall Street analysts.

How have TWST shares performed in 2022?

Twist Bioscience's stock was trading at $77.39 on January 1st, 2022. Since then, TWST shares have decreased by 56.8% and is now trading at $33.44.
View the best growth stocks for 2022 here
.

When is Twist Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our TWST earnings forecast
.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) issued its earnings results on Friday, August, 5th. The company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.30) by $0.22. The company earned $56.10 million during the quarter, compared to analyst estimates of $52.06 million. Twist Bioscience had a negative trailing twelve-month return on equity of 29.61% and a negative net margin of 112.91%. Twist Bioscience's revenue for the quarter was up 60.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.82) EPS.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its FY 2022 earnings guidance on Friday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $203.00 million-$203.00 million, compared to the consensus revenue estimate of $196.91 million.

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.14%), State Street Corp (6.77%), FMR LLC (6.34%), JPMorgan Chase & Co. (5.69%), William Blair Investment Management LLC (4.83%) and Sumitomo Mitsui Trust Holdings Inc. (4.76%). Insiders that own company stock include Bill Peck, Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends
.

How do I buy shares of Twist Bioscience?

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $33.44.

How much money does Twist Bioscience make?

Twist Bioscience (NASDAQ:TWST) has a market capitalization of $1.88 billion and generates $132.33 million in revenue each year. The company earns $-152,100,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.

How many employees does Twist Bioscience have?

The company employs 652 workers across the globe.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.

This page (NASDAQ:TWST) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.